MINNEAPOLIS, July 28, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today ...
$1.15 billion 0.00% Convertible Senior Notes offering (27.50% conversion premium) The repurchase of approximately $460 million of the common stock from investors in the Convertible Notes CleanSpark ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback